How many employees does Guardant health have?

Guardant health

Guardant Health is a pioneer in precision oncology, aiming to help end cancer worldwide by developing and commercializing innovative diagnostic blood tests, collecting and analyzing massive amounts of data, and applying these findings using cutting-edge analytics.

Guardant Health’s oncology platform has the potential to reduce healthcare spending on cancer patients without compromising the quality of treatment they get.

The Guardant360®, Guardant360 CDx, and GuardantOMNI® tests, all based on liquid biopsies, are now available to patients in later stages of cancer treatment.

In contrast, the Guardant RevealTM test is now available to patients in earlier stages of cancer treatment.

The LUNAR screening program uses the results of these tests to create an early detection strategy for those at high risk of getting cancer but shows no symptoms.

Who owns Guardant health?

The Vanguard Group (Inc.)

Is Guardant Health a good company?

Do you think it would be beneficial to work at Guardant Health? Across more than 159 ratings and reviews, workers at Guardant Health gave the company an average score of 3.7 out of 5.

Sixty-seven percent of workers have a good attitude toward the company and would refer friends to work there.

How many employees does Guardant health have?

From 2017 to 2022, Guardant Health will double its workforce. A standard definition of employee count uses the formula: operational cash flow minus capital expenditures represented as a per-share value.

Guardant Health Annual Number of Employees
2021  1,373
2020  864
2019  622
2018  454
2017  348

Guardant health

Read Related Articles: What is Mychart SSM health and How to Use

How large is Guardant health?

Financial Results for the quarter ending March 31, 2022, were released today by Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology firm focused on helping fight cancer worldwide via its unique assays and massive data sets, and sophisticated analytics.

Recent Highlights

  • Earnings of $96.1 million in Q1 2022, up 22.1% from Q1 2021
  • Both clinical and biopharmaceutical testing increased in the first quarter of 2022, with 27,100 tests reported to clinical customers and 5,100 tests reported to biopharmaceutical clients.
  • The shield is the first blood-based test developed by the company for detecting early-stage colorectal cancer, and it was released as a Laboratory Developed Test (LDT).
  • Over 250 million patients in the United States have a record in Epic, a widely utilized complete health record system, according to the company’s recently announced relationship with Epic.
  • Keytruda® and Opdivo® may effectively treat patients with microsatellite instability-high (MSI-High) solid tumors. The Japanese government has approved the companion diagnostic Guardant360® CDx for this purpose in patients with advanced solid malignancies.
  • Coverage for the Guardant360 TissueNextTM test has been approved for use by Medicare as part of the Molecular Diagnostics Services program (MolDX) LCD.

Guardant’s high-performance testing portfolio and excellent customer service have helped to position the company as the market leader in liquid biopsy, according to Helmy Eltoukhy, co-founder and co-CEO.

More than 11,000 oncologists are already utilizing Guardant solutions, and quarterly growth in test orders and product use from existing clients is a positive sign.

With the support of the data supplied by our cutting-edge blood tests, we are helping patients at every stage of cancer treatment to live longer and better lives.

Introducing our newest products has given us a significant boost in this direction.

According to Amiri Talasaz, co-founder and co-CEO, “the recent introduction of our Shield LDT screening test is a huge milestone in our quest to change cancer screening.”

If the results of the ECLIPSE study are similar to those of our LDT validation, we do not doubt that shield will overtake all other non-invasive CRC screening methods. Regular screening for colorectal cancer is the first step.

We are confident that cancer screening may save lives, and thus we want to shortly extend into the high-sensitivity multi-cancer screening that will include the lungs and pancreas.

Financial Results for the First Quarter of 2022

For the three months ending in March of 2022, revenue was $96.1 million, up 22% from the $78.7 million recorded in the same period in 2021.

Increases in clinical testing volume (up 47%) and biopharma sample volume (up 45%) were the primary contributors to the 32% year-over-year growth in precision oncology revenue.

The discontinuation of our Guardant-19 COVID tests in August 2021 and the progression of collaboration projects with biopharmaceutical customers for companion diagnostic development and regulatory approval services contributed to a 20% decline in development services and other revenue for the three months ended March 31, 2022, which was partially offset by royalty revenues.

For the first quarter of 2022, gross profit was $64.1 million, an increase of $14.2 million over the $49.9 million recorded in the previous year’s first quarter.

This figure excludes the cost of precision oncology testing and the cost of development services, and others. The gross margin (gross profit as a percentage of total sales) was 67%, up from 63% at the same time last year.

Operating costs in the first quarter of 2022 were $187.5 million, up 19% from the same period a year earlier, when they were $157.8 million.

For the first quarter of 2022, operational costs were $158.7 million, up from $100.7 million in the first quarter of 2021.

For the first quarter of 2022, Guardant Health, Inc. reported a $123.2 million net loss attributable to common shareholders, up from a loss of $109.7 million in the first quarter of 2021.

For the first quarter of 2022, the net loss per share attributable to Guardant Health, Inc. common shareholders was $1.21, up from $1.09 in the first quarter of 2021.

The company reported a net loss of $93.2 million in Q1 2022, compared to a loss of $49.4 million in Q1 2021, according to non-GAAP accounting.

Non-GAAP net loss per share for the first quarter of 2022 was $0.91, up from $0.49 in the first quarter of 2021.

Comparing the first quarter of 2022 to the first quarter of the previous year, the loss in adjusted EBITDA was $86.6 million, up from a loss of $45.4 million.

As of March 31, 2022, we had $1.6 billion in liquid assets (cash, equivalents in kind, and marketable securities).

2022 Guidance

Guardant Health’s revenue forecast for 2022 remains unchanged at between $460 million and $470 million, indicating 23% to 26% growth from 2021’s full-year totals.

Webcast Information

On Wednesday, May 5, 2022, at 1:30 pm Pacific Time / 4:30 pm Eastern Time, Guardant Health will have a conference call to review the company’s financial results for the first quarter of 2022.

There will be a live webcast of the conference call available at http://investors.guardanthealth.com. Viewers may access the webcast’s archived recording for at least 90 days following the event.

Non-GAAP Measures

In this release, Guardant Health presents financial data in accordance with GAAP and non-GAAP.

This data includes the cost of precision oncology testing, the cost of research and development, the cost of sales and marketing, the cost of general and administrative expenses, the loss from operations, the net loss, the portion of the net loss attributable to Guardant Health, Inc., and the common stockholders’ equity.

Stock-based compensation and corresponding employer payroll tax payments, changes in estimated fair value of redeemable noncontrolling interest, contingent consideration, acquisition-related expenditures, amortization of intangible assets, and other non-recurring factors are excluded from our non-GAAP measurements.

Interest income, interest expense, other income (expense), net, provision for (benefit from) income taxes, depreciation, and amortization expense, stock-based compensation expense and related employer payroll tax payments, adjustments relating to redeemable noncontrolling interest and contingent consideration, and if applicable in a reporting period, acquisition-related costs are all subtracted from the net loss attributable to Guardant Health, Inc. common stockholders to arrive at Adjusted EBITDA.

We think that removing specific revenue and costs in computing these non-GAAP financial metrics might offer a meaningful gauge for investors when comparing our core operational performance from period to period and from our disclosed peers.

We also don’t include other sources of revenue (expenses) since we don’t think they accurately represent future operational costs.

To further complicate matters, several components are inconsistent in quantity and frequency, making it hard to evaluate our current or historical operational performance accurately.

These measurements are used for internal planning and forecasting and company management and are not considered standard by the GAAP.

These non-GAAP financial statements should not be seen in a vacuum, as a replacement for, or as an improvement over their comparable GAAP measurements.

Non-GAAP financial metrics have inherent limitations due to their omission of charges and credits that are needed to be included in a GAAP presentation and their failure to reflect the full measure of our recorded expenses against its revenue.

In addition, the non-GAAP financial metrics we employ may be defined differently from the non-GAAP financial measures used by other firms.

Guardant health

Read Related Articles: Team Dignity Health email login(Update)

Is Guardant Health publicly traded?

The public offering price of $19.00 per share has been set for the first public offering of 12,500,000 shares of common stock by Guardant Health, Inc. (Nasdaq: GH).

Guardian Health is offering all of the available common stock. Guardian Health also gave the underwriters a 30-day option to buy up to an additional 1,875,000 shares of common stock at the public offering price, minus the underwriting discounts and fees.

The common stock of Guardant Health is scheduled to begin trading on the Nasdaq Global Select Market under the symbol “GH” on October 4, 2018.

Excluding any exercise of the underwriters’ option to acquire further shares, the total proceeds from the offering are projected to be $237.5 million.

This amount does not include underwriting discounts, commissions, or other offering costs payable by Guardian Health. Subject to the fulfillment of customary closing conditions, the offering is scheduled to close on October 9, 2018.

Guardant Health careers

See Open Position

Guardant Health benefits

What advantages can Guardant Health offer?

  • Health and Wellness Insurance Healthcare Coverage. 4.5
  • Money and Retirement; 401(k) Strategy. 3.3
  • Family & Parenting. Maternity & Paternity Leave. 3.7★
  • Vacation & Time Off. Paid time off (including vacation), and other paid leave. 3.8★
  • Discounts & Benefits. Food and snacks are provided at no cost.
  • Development of your professional network.

More Resources: 

Leave a Reply

Your email address will not be published.